Buy the Dip in Pfizer, Here’s Why By StockNews

© Reuters. Buy the Dip in Pfizer, Here’s Why

The world’s premier biopharmaceutical company Pfizer’s (PFE) COVID-19 vaccine approval by the FDA marked a breakthrough achievement in the world’s battle with the COVID-19 pandemic. As the company prepares to roll out booster doses, it is well-positioned to see strong sales growth in the near term. And now that the stock is trading below its 52-week price high, we believe it’s the perfect time to scoop up its shares. So, let’s discuss.Global biopharmaceutical company Pfizer Inc. (NYSE:), which is based in New York City, manufactures, markets, and sells medicines and vaccines worldwide. The New York-based vaccine maker catapulted into the limelight after producing the Pfizer-BioNTech COVID-19 vaccine last year. It is now marketed as Comirnaty, for preventing COVID-19 disease in individuals 16 years of age and older. PFE’s shares have rallied 20.2% in price over the past three months, driven by news of its COVID-19 vaccine becoming the first of its kind to be fully approved by the U.S. Food and Drug Administration.

Closing yesterday’s session at $46.75, PFE is trading just 9.9% below its 52-week price high of $51.86. As COVID-19 cases in the United States hit 40 million, more unvaccinated individuals are likely to go for the FDA-approved vaccine amid the rapid spread of the virus’ Delta variant. Furthermore, as the company prepares to roll out its booster shots, the drugmaker should witness a strong surge in sales in the coming months.

In addition, PFE raised its 2021 financial guidance for the second consecutive quarter due to increased expected contributions from its COVID-19-related and mRNA-based programs, as well as other business segments.

Continue reading on StockNews

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.